SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934(Amendment No.: 1)* Name...
0001741830FALSE00017418302023-01-212023-01-21UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-KCURRENT REPORT...
0001741830FALSE00017418302023-01-062023-01-06UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-KCURRENT REPORT...
Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cooper Co (COO – Research Report), COMPASS Pathways (CMPS –...
E ratio of -0.59.https://www.tipranks.com/news/blurbs/kronos-bio-kron-gets-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Kronos Bio to move into Phase 2 stage of study, evaluating compound in patients with MYC-amplified and other...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a...
Kronos Bio (KRON - Research Report) received a Buy rating and an $11.00 price target from Berenberg Bank analyst Zhiqiang Shu on November 18. The...
Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.